RGD DISEASE ONTOLOGY - ANNOTATIONS
RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.
Term: Drug-Induced Dyskinesia
Accession: DOID:9008394
browse the term
Definition: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
Synonyms: exact_synonym: Drug-Induced Dyskinesias; Medication Induced Dyskinesia; Medication-Induced Dyskinesias
primary_id: MESH:D004409
xref: EFO:1000904
G
ABAT
4-aminobutyrate aminotransferase
ISO
RGD
PMID:7740056 PMID:6445277
RGD:1598524 , RGD:10047091
NCBI chr16:8,674,617...8,784,570
Ensembl chr16:8,674,596...8,784,575
G
CACNA1D
calcium voltage-gated channel subunit alpha1 D
ISO
RGD
PMID:18947822
RGD:6906919
NCBI chr 3:53,494,611...53,813,733
Ensembl chr 3:53,328,963...53,813,733
G
CAT
catalase
EXP
CTD Direct Evidence: marker/mechanism
CTD
PMID:19109989
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
G
CCK
cholecystokinin
EXP
CTD Direct Evidence: therapeutic
CTD
PMID:2320253
NCBI chr 3:42,257,826...42,266,185
Ensembl chr 3:42,257,825...42,266,185
G
COMT
catechol-O-methyltransferase
ISO
RGD
PMID:16437585
RGD:2289781
NCBI chr22:19,941,772...19,969,975
Ensembl chr22:19,941,371...19,969,975
G
CYP2D6
cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)
IAGP
RGD
PMID:12629505
RGD:1358549
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
G
DBN1
drebrin 1
ISO
levodopainduced; protein:increased expression:striatum:
RGD
PMID:23241013
RGD:10398811
NCBI chr 5:177,456,610...177,473,634
Ensembl chr 5:177,456,608...177,474,401
G
DDC
dopa decarboxylase
ISO
associated with Parkinson Disease; protein:decreased expression:striatum (rat)
RGD
PMID:20232137
RGD:5128860
NCBI chr 7:50,458,442...50,565,405
Ensembl chr 7:50,458,436...50,565,405
G
DRD1
dopamine receptor D1
EXP
CTD Direct Evidence: marker/mechanism
CTD
PMID:7845605 PMID:10858612 PMID:16982285 PMID:19520364
NCBI chr 5:175,440,036...175,444,182
Ensembl chr 5:175,440,036...175,444,182
G
DRD2
dopamine receptor D2
ISO EXP
CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:7845605 PMID:10534246 PMID:14629710 PMID:18707801
RGD:2311579
NCBI chr11:113,409,605...113,475,398
Ensembl chr11:113,409,605...113,475,691
G
DRD3
dopamine receptor D3
EXP
CTD Direct Evidence: marker/mechanism
CTD
PMID:20945430
NCBI chr 3:114,127,580...114,199,407
Ensembl chr 3:114,127,580...114,199,407
G
EGR1
early growth response 1
ISO
RGD
PMID:22153973
RGD:10395307
NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
G
FOSB
FosB proto-oncogene, AP-1 transcription factor subunit
EXP
CTD Direct Evidence: marker/mechanism
CTD
PMID:17219962
NCBI chr19:45,467,996...45,475,179
Ensembl chr19:45,467,995...45,475,179
G
GAD1
glutamate decarboxylase 1
EXP
CTD Direct Evidence: marker/mechanism
CTD
PMID:9767399
NCBI chr 2:170,813,210...170,861,151
Ensembl chr 2:170,813,213...170,861,151
G
GCH1
GTP cyclohydrolase 1
EXP
CTD Direct Evidence: therapeutic
CTD
PMID:15659429
NCBI chr14:54,842,017...54,902,826
Ensembl chr14:54,842,008...54,902,826
G
GDNF
glial cell derived neurotrophic factor
EXP
CTD Direct Evidence: therapeutic
CTD
PMID:11168568
NCBI chr 5:37,812,677...37,840,041
Ensembl chr 5:37,812,677...37,840,041
G
GLUL
glutamate-ammonia ligase
ISO
RGD
PMID:6445277
RGD:10047091
NCBI chr 1:182,378,098...182,391,790
Ensembl chr 1:182,378,098...182,392,206
G
GRK6
G protein-coupled receptor kinase 6
ISO
associated with Parkinson Disease
RGD
PMID:20410529
RGD:5684919
NCBI chr 5:177,425,523...177,442,891
Ensembl chr 5:177,403,204...177,442,901
G
GSK3B
glycogen synthase kinase 3 beta
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:26997328
RGD:13792768
NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994
G
HOMER1
homer scaffold protein 1
EXP
CTD Direct Evidence: marker/mechanism
CTD
PMID:24126708
NCBI chr 5:79,372,636...79,514,134
Ensembl chr 5:79,372,636...79,514,134
G
HTR1A
5-hydroxytryptamine receptor 1A
ISO
RGD
PMID:21352823
RGD:5683628
NCBI chr 5:63,957,874...63,962,445
Ensembl chr 5:63,957,874...63,962,507
G
MAPT
microtubule associated protein tau
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:25511986
RGD:13800920
NCBI chr17:45,894,554...46,028,334
Ensembl chr17:45,894,527...46,028,334
G
MTOR
mechanistic target of rapamycin kinase
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:23938307
RGD:10040953
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
G
PDYN
prodynorphin
treatment severity
EXP ISO
CTD Direct Evidence: marker/mechanism associated with Parkinsonism associated with Parkinsonism;protein:increased expression:striatum
CTD RGD
PMID:9767399 PMID:21737418 PMID:10869049 PMID:17884291 PMID:21737418
RGD:401900134 , RGD:401851046 , RGD:401850563
NCBI chr20:1,978,756...1,994,285
Ensembl chr20:1,978,757...1,994,285
G
PENK
proenkephalin
treatment disease_progression
ISO EXP
mRNA:increased expression:brain:striatum: associated with Parkinsonism associated with Parkinsonism;mRNA:increased expression:striatum CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:9767399 PMID:20456008 PMID:10869049 PMID:26113400
RGD:10003039 , RGD:401900134 , RGD:401851054
NCBI chr 8:56,440,957...56,446,641
Ensembl chr 8:56,436,674...56,446,671
G
PPP1R1B
protein phosphatase 1 regulatory inhibitor subunit 1B
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:27771532
RGD:13514053
NCBI chr17:39,626,707...39,636,624
Ensembl chr17:39,626,740...39,636,626
G
RASGRF1
Ras protein specific guanine nucleotide releasing factor 1
EXP
CTD Direct Evidence: therapeutic
CTD
PMID:21115823
NCBI chr15:78,959,906...79,090,780
Ensembl chr15:78,959,906...79,090,780
G
RELA
RELA proto-oncogene, NF-kB subunit
ISO
protein:increased expression:nucleus, brain
RGD
PMID:18590723
RGD:2298778
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
G
RGS4
regulator of G protein signaling 4
treatment
ISO
associated with Parkinsonian Disorders
RGD
PMID:24969021
RGD:13524515
NCBI chr 1:163,068,871...163,076,802
Ensembl chr 1:163,068,775...163,076,802
G
RGS9
regulator of G protein signaling 9
EXP
CTD Direct Evidence: marker/mechanism|therapeutic
CTD
PMID:18160641 PMID:24663062
NCBI chr17:65,137,370...65,227,703
Ensembl chr17:65,100,812...65,227,703
G
TH
tyrosine hydroxylase
EXP
CTD Direct Evidence: therapeutic
CTD
PMID:15659429
NCBI chr11:2,163,929...2,171,815
Ensembl chr11:2,163,929...2,171,815
G
CYP1A2
cytochrome P450 family 1 subfamily A member 2
treatment
IAGP
associated with schizophrenia
RGD
PMID:10889552
RGD:1358545
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
G
DRD3
dopamine receptor D3
IAGP
associated with schizophrenia
RGD
PMID:12960753
RGD:1581250
NCBI chr 3:114,127,580...114,199,407
Ensembl chr 3:114,127,580...114,199,407
G
SOD2
superoxide dismutase 2
IAGP
associated with schizophrenia
RGD
PMID:12960753
RGD:1581250
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all